APS — Aptose Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- CA$32.83m
- CA$8.72m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15.7 | 97.6 | 122 | 79.1 | 47 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 16.5 | 98.8 | 125 | 81.7 | 49.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.384 | 1.71 | 1.19 | 0.788 | 1.51 |
Total Assets | 16.9 | 100 | 126 | 82.5 | 51 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 2.79 | 5.54 | 6.81 | 8.17 | 12.3 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.79 | 6.55 | 7.35 | 8.29 | 13.3 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 14.1 | 93.9 | 119 | 74.2 | 37.7 |
Total Liabilities & Shareholders' Equity | 16.9 | 100 | 126 | 82.5 | 51 |
Total Common Shares Outstanding |